MX2023003087A - Compuesto de pirimido pirimidinona y composicion farmaceutica que comprenden el mismo. - Google Patents
Compuesto de pirimido pirimidinona y composicion farmaceutica que comprenden el mismo.Info
- Publication number
- MX2023003087A MX2023003087A MX2023003087A MX2023003087A MX2023003087A MX 2023003087 A MX2023003087 A MX 2023003087A MX 2023003087 A MX2023003087 A MX 2023003087A MX 2023003087 A MX2023003087 A MX 2023003087A MX 2023003087 A MX2023003087 A MX 2023003087A
- Authority
- MX
- Mexico
- Prior art keywords
- pharmaceutical composition
- same
- pyrimidino
- pyrimidinone compound
- pyrimidinone
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20200119100 | 2020-09-16 | ||
| PCT/KR2021/012616 WO2022060094A1 (ko) | 2020-09-16 | 2021-09-15 | 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023003087A true MX2023003087A (es) | 2023-04-14 |
Family
ID=80777269
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023003087A MX2023003087A (es) | 2020-09-16 | 2021-09-15 | Compuesto de pirimido pirimidinona y composicion farmaceutica que comprenden el mismo. |
Country Status (11)
| Country | Link |
|---|---|
| US (1) | US12590098B2 (https=) |
| EP (1) | EP4215533B1 (https=) |
| JP (1) | JP7824667B2 (https=) |
| KR (1) | KR102673031B1 (https=) |
| CN (1) | CN116137815B (https=) |
| AU (1) | AU2021344164A1 (https=) |
| BR (1) | BR112023004179A2 (https=) |
| CA (1) | CA3190461A1 (https=) |
| IL (1) | IL300920A (https=) |
| MX (1) | MX2023003087A (https=) |
| WO (1) | WO2022060094A1 (https=) |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MXPA06001098A (es) * | 2003-07-29 | 2006-04-24 | Irm Llc | Compuestos y composiciones utiles como inhibidores de proteina cinasa. |
| BRPI0514738A (pt) | 2004-08-31 | 2008-06-24 | Hoffmann La Roche | derivados de amida de 3-fenil-diidropirimido[4,5-d]pirimidinonas, sua fabricação e aplicação como agentes farmacêuticos |
| UY29439A1 (es) * | 2005-03-25 | 2006-10-02 | Glaxo Group Ltd | Nuevos compuestos |
| RU2007147917A (ru) * | 2005-06-10 | 2009-07-20 | Айрм Ллк (Bm) | Соединения, поддерживающие плюрипотентность эмбриональных стволовых клеток |
| EP2455382B1 (en) | 2005-12-13 | 2016-10-26 | Incyte Holdings Corporation | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as Janus kinase inhibitors |
| GB201315072D0 (en) | 2013-08-23 | 2013-10-02 | Galapagos Nv | Novel compounds and pharmaceutical compositions thereoffor the treatment of proliferative disorders |
| AU2017291812B2 (en) * | 2016-07-05 | 2023-12-14 | Dana-Farber Cancer Institute, Inc. | Bicyclic urea kinase inhibitors and uses thereof |
| KR102591947B1 (ko) * | 2018-04-19 | 2023-10-25 | 길리애드 사이언시즈, 인코포레이티드 | Pd-1/pd-l1 억제제 |
| KR102382613B1 (ko) * | 2020-01-15 | 2022-04-06 | 한국과학기술연구원 | 단백질 키나아제 저해 활성을 갖는 7-아미노-3,4-디히드로피리미도피리미딘-2-온 유도체 및 이를 포함하는 치료용 약학 조성물 |
-
2021
- 2021-09-15 MX MX2023003087A patent/MX2023003087A/es unknown
- 2021-09-15 CA CA3190461A patent/CA3190461A1/en active Pending
- 2021-09-15 JP JP2023515773A patent/JP7824667B2/ja active Active
- 2021-09-15 EP EP21869716.7A patent/EP4215533B1/en active Active
- 2021-09-15 IL IL300920A patent/IL300920A/en unknown
- 2021-09-15 KR KR1020210123331A patent/KR102673031B1/ko active Active
- 2021-09-15 CN CN202180063334.1A patent/CN116137815B/zh active Active
- 2021-09-15 WO PCT/KR2021/012616 patent/WO2022060094A1/ko not_active Ceased
- 2021-09-15 US US18/245,395 patent/US12590098B2/en active Active
- 2021-09-15 BR BR112023004179A patent/BR112023004179A2/pt unknown
- 2021-09-15 AU AU2021344164A patent/AU2021344164A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| EP4215533B1 (en) | 2026-02-11 |
| CN116137815A (zh) | 2023-05-19 |
| BR112023004179A2 (pt) | 2023-04-11 |
| US20230348474A1 (en) | 2023-11-02 |
| JP7824667B2 (ja) | 2026-03-05 |
| KR20220036895A (ko) | 2022-03-23 |
| EP4215533A4 (en) | 2024-12-18 |
| IL300920A (en) | 2023-04-01 |
| WO2022060094A1 (ko) | 2022-03-24 |
| JP2023541052A (ja) | 2023-09-27 |
| CN116137815B (zh) | 2025-08-19 |
| KR102673031B1 (ko) | 2024-06-07 |
| CA3190461A1 (en) | 2022-03-24 |
| AU2021344164A9 (en) | 2024-03-21 |
| AU2021344164A1 (en) | 2023-05-04 |
| US12590098B2 (en) | 2026-03-31 |
| EP4215533A1 (en) | 2023-07-26 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CL2023002383A1 (es) | Compuesto de quinazolina para inducir la degradación de la proteína kras mutante g12d | |
| CO2024008543A2 (es) | Composición farmacéutica que comprende un compuesto de quinazolina | |
| CL2021003477A1 (es) | Compuestos 2,3-dihidroquinazolin como inhibidores nav1 .8 | |
| CL2021001292A1 (es) | Terapia de combinación que incluye un inhibidor de krasg12c y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cánceres | |
| JOP20220163B1 (ar) | مركب بيريدازينيل-ثيازول كربوكساميد | |
| MX2018002520A (es) | Compuesto novedoso de pirazolo[3,4-d] pirimidina o sal del mismo. | |
| EP4360713A3 (en) | Quinazoline derivatives as antitumor agents | |
| MX2023009011A (es) | Inhibidor de cdk. | |
| CO2019005287A2 (es) | Compuestos de 7-feniletilamino-4h-pirimido[4,5-d][1,3]-oxazin-2-ona como inhibidores de idh1 e idh2 mutantes | |
| MX2022013410A (es) | Metodos de tratamiento. | |
| SV2018005742A (es) | Inhibidores de mcl-1 macrocíclicos para tratar el cáncer | |
| MX2019009853A (es) | Terapia de combinacion que incluye un inhibidor mdm2 y uno o mas agentes farmaceuticamente activos adicionales para el tratamiento de canceres. | |
| CL2018000706A1 (es) | Derivados de pirazolopirimidina como inhibidores btk para el tratamiento del cancer. | |
| CL2023003965A1 (es) | Inhibidores cdk2. | |
| CO2023008271A2 (es) | Compuesto de heteroarilcarboxamida | |
| MX2022013081A (es) | Compuestos para el tratamiento de sars. | |
| MX2022008478A (es) | Combinaciones de brimonidina de dosis baja y usos de las mismas. | |
| MX2021015770A (es) | Inhibidores macrociclicos de mcl-1. | |
| MX2023003087A (es) | Compuesto de pirimido pirimidinona y composicion farmaceutica que comprenden el mismo. | |
| CL2021003442A1 (es) | Composición farmacéutica que comprende idelalisib y defactinib; y métodos para el tratamiento de cáncer. | |
| MX392672B (es) | Composicion combinada para prevenir o tratar cancer que comprende un derivado de benzofenona tiazol como un vda e inhibidor de topoisomerasa. | |
| MX2024001154A (es) | Tratamiento del eczema de manos con baricitinib. | |
| CL2019001046A1 (es) | Terapia de combinación que incluye un inhibidor mdm2 y uno o más agentes farmacéuticamente activos adicionales para el tratamiento de cáncer. (divisional solicitud 201601131) | |
| DOP2025000073A (es) | Combinación de compuestos de 2,4 diamino-quinolina sustituida e inhibidores de la proteína quinasa quinasa activada por mitógeno (mek) para ser utilizada en el tratamiento de cánceres hepáticos |